Nimotuzumab

• CAT Number: I044211
• CAS Number: 780758-10-3
• Purity: ≥95%

Nimotuzumab（Cat No.:I044211）is a humanized IgG1 monoclonal antibody that targets the epidermal growth factor receptor (EGFR), which is overexpressed in many epithelial tumors. By binding to EGFR, nimotuzumab inhibits ligand-induced receptor activation, thereby blocking downstream signaling pathways involved in cell proliferation, angiogenesis, and survival. It is used in the treatment of cancers such as glioma, head and neck squamous cell carcinoma, and nasopharyngeal carcinoma. Notably, nimotuzumab has a favorable safety profile with lower skin toxicity compared to other EGFR inhibitors, making it suitable for long-term cancer therapy.